» Articles » PMID: 3528901

Concentration of Striatal Tyramine and Dopamine Metabolism in Diabetic Rats and Effect of Insulin Administration

Overview
Publisher Karger
Specialties Endocrinology
Neurology
Date 1986 Jan 1
PMID 3528901
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Earlier work has shown that diabetic rats possess lower concentrations of brain p-tyrosine; these animals also show a decrease in the rate of accumulation of striatal DOPA after decarboxylase inhibition and an increase in striatal binding sites for dopamine. These findings suggested that diabetic rats show a reduction in the metabolism of brain dopamine. This is an investigation of the effects of streptozotocin-induced (65 mg/kg, intracardially) diabetes on rat striatal concentrations of p-tyrosine, p-tyramine, m-tyramine, dopamine, 3,4-dihydroxyphenylacetic acid and homovanillic acid. Also, the effects of insulin administration (0.5-4 IU/kg, intraperitoneally) to normal and diabetic rats were studied. The onset of diabetes or effect of insulin treatment was determined by the changes produced in blood glucose. Streptozotocin produced a significant reduction in the striatal concentration of p-tyrosine, 3,4-dihydroxyphenylacetic acid and homovanillic acid observed 7 or 14 days after injection. The treatment produced a reduction in p-tyramine and an increase in m-tyramine. Insulin administration significantly increased rat striatal p-tyrosine, p-tyramine, 3,4-dihydroxyphenylacetic acid and homovanillic acid while m-tyramine was decreased. The concentrations of p-tyrosine, dopamine, 3,4-dihydroxyphenylacetic acid and homovanillic acid in the striatum of insulin-treated diabetic rats were within the range of control values. The results indicate that streptozotocin-diabetic rats possess a reduced striatal dopamine metabolism and that this is counteracted by insulin administration. These changes are probably the consequence of changes in the availability of some amino acid precursors and in tyrosine hydroxylase activity.

Citing Articles

Dopamine in the Regulation of Glucose Homeostasis, Pathogenesis of Type 2 Diabetes, and Chronic Conditions of Impaired Dopamine Activity/Metabolism: Implication for Pathophysiological and Therapeutic Purposes.

Lisco G, De Tullio A, Iovino M, Disoteo O, Guastamacchia E, Giagulli V Biomedicines. 2023; 11(11).

PMID: 38001993 PMC: 10669051. DOI: 10.3390/biomedicines11112993.


Diabetes and Cognitive Impairment: A Role for Glucotoxicity and Dopaminergic Dysfunction.

Pignalosa F, Desiderio A, Mirra P, Nigro C, Perruolo G, Ulianich L Int J Mol Sci. 2021; 22(22).

PMID: 34830246 PMC: 8619146. DOI: 10.3390/ijms222212366.


Metabolomic analysis of healthy human urine following administration of glimepiride using a liquid chromatography-tandem mass spectrometry.

Do E, Gwon M, Kim B, Ohk B, Lee H, Kang W Transl Clin Pharmacol. 2020; 25(2):67-73.

PMID: 32133322 PMC: 7042006. DOI: 10.12793/tcp.2017.25.2.67.


Syndrome of uremic encephalopathy and bilateral basal ganglia lesions in non-diabetic hemodialysis patient: a case report.

Gong W, Li S, Yu Z, Wu H, Yin L, Mei L BMC Nephrol. 2018; 19(1):370.

PMID: 30567505 PMC: 6299987. DOI: 10.1186/s12882-018-1174-0.


Uremic Encephalopathy: MR Imaging Findings and Clinical Correlation.

Kim D, Lee I, Song C AJNR Am J Neuroradiol. 2016; 37(9):1604-9.

PMID: 27127003 PMC: 7984681. DOI: 10.3174/ajnr.A4776.